NeoGenomics, Inc. (NEO)
NeoGenomics, Inc. is a biotechnology company specializing in cancer genetics testing and clinical trial services. It focuses on providing advanced molecular testing and diagnostic services to oncologists, pharmaceutical companies, and researchers to improve cancer detection, diagnosis, and treatment. Founded in 2002, the company operates labs across the United States and is committed to innovation in cancer genomics.
Company News
Insider activity increased in stocks such as Hudson Pacific Properties, NeoGenomics, and Carvana, signaling opportunities for traders and investors. The article examines who is buying, the forces driving their underlying markets, and the potential upside.
The Minimal Residual Disease (MRD) Testing Market is expected to grow at a CAGR of 11.18% from 2025 to 2030, driven by advancements in diagnostic technologies and the increasing focus on precision medicine and early relapse detection.
The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.
While the top- and bottom-line numbers for NeoGenomics (NEO) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.